Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q2 2015 · 10-Q
Revenue$12.11K$12.11K— vs Q2 2014 Net Income-$1.56M-$1.56MN/M vs Q2 2014 EPS Diluted-$0.04-$0.04— vs Q2 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
-$1,560,499
N/M
Operating Cash Flowderived-$163,702— Margins · derivedGross margin100.0%
Operating margin-12883.9%
Net margin-12885.5%
ended Jun 30, 2015 · filed Aug 19, 2015 · 50 d after period end